Vir Biotechnology
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2016-04-07
- Employees
- 587
- Market Cap
- -
- Website
- http://www.vir.bio
- Introduction
Vir Biotechnology, Inc. operates as a clinical-stage immunology company that focuses on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. The firm's technology platforms include antibody, T cell, innate immunity and siRNA, which are designed to stimulate and enhance the immune system by exploiting...
Study of VIR-2218, VIR-3434, And/or PEG-IFNα in Subjects with Chronic Hepatitis B Virus Infection
- Conditions
- Interventions
- First Posted Date
- 2021-04-22
- Last Posted Date
- 2024-11-21
- Lead Sponsor
- Vir Biotechnology, Inc.
- Target Recruit Count
- 244
- Registration Number
- NCT04856085
- Locations
- 🇬🇧
Investigative Site, Manchester, United Kingdom
Safety, Tolerability and Pharmacokinetics of Second Generation VIR-7831 Material in Non-hospitalized Participants With Mild to Moderate COVID-19
- Conditions
- Interventions
- First Posted Date
- 2021-03-03
- Last Posted Date
- 2023-05-03
- Lead Sponsor
- Vir Biotechnology, Inc.
- Target Recruit Count
- 354
- Registration Number
- NCT04779879
- Locations
- 🇪🇸
Investigative Site, Vigo, Spain
VIR-1111: A Prototype Human CMV-based Vaccine for Human Immunodeficiency Virus (HIV) in Healthy Volunteers
- First Posted Date
- 2021-01-27
- Last Posted Date
- 2023-02-27
- Lead Sponsor
- Vir Biotechnology, Inc.
- Target Recruit Count
- 27
- Registration Number
- NCT04725877
- Locations
- 🇺🇸
Investigative Site, Madison, Wisconsin, United States
VIR-7831 for the Early Treatment of COVID-19 in Outpatients
- First Posted Date
- 2020-09-10
- Last Posted Date
- 2022-11-07
- Lead Sponsor
- Vir Biotechnology, Inc.
- Target Recruit Count
- 1057
- Registration Number
- NCT04545060
- Locations
- 🇬🇧
Investigative Site, Belfast, United Kingdom
Study of VIR-3434 in Healthy Volunteers and Patients With Chronic Hepatitis B Virus Infection
- First Posted Date
- 2020-06-09
- Last Posted Date
- 2024-10-08
- Lead Sponsor
- Vir Biotechnology, Inc.
- Target Recruit Count
- 113
- Registration Number
- NCT04423393
- Locations
- 🇬🇧
Investigative Site, Manchester, United Kingdom
Study of VIR-2218 With or Without Pegylated Interferon Alpha-2a for Treatment of Chronic Hepatitis B Virus Infection
- Conditions
- Interventions
- First Posted Date
- 2020-06-02
- Last Posted Date
- 2024-05-03
- Lead Sponsor
- Vir Biotechnology, Inc.
- Target Recruit Count
- 84
- Registration Number
- NCT04412863
- Locations
- 🇹🇭
Investigative Site, Khon Kaen, Thailand
🇭🇰Investigative site, Hong Kong, Hong Kong
Study of VIR-2482 in Healthy Volunteers
- First Posted Date
- 2019-07-26
- Last Posted Date
- 2022-06-09
- Lead Sponsor
- Vir Biotechnology, Inc.
- Target Recruit Count
- 100
- Registration Number
- NCT04033406
- Locations
- 🇦🇺
Investigative Site, Brisbane, Queensland, Australia
Study of VIR-2218 in Healthy Subjects and Patients With Chronic Hepatitis B
- First Posted Date
- 2018-09-14
- Last Posted Date
- 2021-12-13
- Lead Sponsor
- Vir Biotechnology, Inc.
- Target Recruit Count
- 82
- Registration Number
- NCT03672188
- Locations
- 🇹🇭
Investigative Site, Khon Kaen, Thailand